Autolus Therapeutics (AUTL) Operating Expenses (2017 - 2025)

Autolus Therapeutics (AUTL) has 9 years of Operating Expenses data on file, last reported at $96.8 million in Q4 2025.

• For the quarter ending Q4 2025, Operating Expenses rose 27.49% year-over-year to $96.8 million; the trailing twelve-month figure through Dec 2025 stood at $345.9 million (up 37.52% YoY), and the FY2025 full-year result was $345.9 million, up 37.52% from the prior year.
• Operating Expenses for Q4 2025 stood at $96.8 million, up from $92.8 million in the prior quarter.
• Across five years, Operating Expenses topped out at $320.2 million in Q4 2023 and bottomed at -$40.4 billion in Q3 2021.
• The 5-year median for Operating Expenses is $31.9 million (2022), against an average of -$2.0 billion.
• The widest annual swing landed in 2021, when Operating Expenses tumbled 94390.49%; it then surged 2040.47% in 2023.
• A 5-year view of Operating Expenses shows it stood at $262.1 million in 2021, then slumped by 94.29% to $15.0 million in 2022, then soared by 2040.47% to $320.2 million in 2023, then slumped by 76.3% to $75.9 million in 2024, then increased by 27.49% to $96.8 million in 2025.
• The last three Operating Expenses figures came in at $96.8 million (Q4 2025), $92.8 million (Q3 2025), and $82.1 million (Q2 2025), per Business Quant data.

Peer Comparison